Key Takeaways
- • Patria Private Equity Trust PLC appointed Nigel Reynolds as a Non-Executive Director, effective 17 November 2026, per an RNS announcement dated 11 November 2026.
- • Reynolds is intended, after a transition period, to succeed Calum Thomson as chair of the Audit and Risk Committee; Thomson retires from the Board at the AGM in March 2027.
- • Yvonne Stillhart will succeed Calum Thomson as Senior Independent Director, effective 17 November 2026.
- • Reynolds brings 34 years of accounting and finance experience, including 20 years as a PwC partner until his retirement in December 2025.
Summary
Patria Private Equity Trust PLC announced on 11 November 2026 through a Regulatory News Service (RNS) filing that its Board has appointed Nigel Reynolds as a Non-Executive Director with effect from 17 November 2026. The company described the appointment as part of its ongoing succession planning. After a transition period, Reynolds is expected to be appointed chair of the Company's Audit and Risk Committee, replacing Calum Thomson, who will retire from the Board at the Annual General Meeting in March 2027.
In a related change, Yvonne Stillhart will succeed Calum Thomson as Senior Independent Director, also with effect from 17 November 2026.
Reynolds has 34 years of accounting and finance experience advising listed and private companies. He was a partner at PwC for 20 years, specialising in audit, transaction services and capital markets, and retired in December 2025. At PwC he led the London Assurance practice and the private equity portfolio company practice, and served as relationship partner for several UK-listed and international companies, including investment trusts. His advisory work has also covered strategy, M&A, internal audit and tax. Reynolds currently serves as a Non-Executive Director of Biopharma Credit PLC, an investment trust providing debt capital to the life sciences industry, and of the law firm Simmons & Simmons.
The company stated that no further information is required to be disclosed under UKLR 6.4.8 of the Financial Conduct Authority Listing Rules. Investor queries may be directed to Holly Kidd, Company Secretary, at GPMS Corporate Secretary Limited.
In a related change, Yvonne Stillhart will succeed Calum Thomson as Senior Independent Director, also with effect from 17 November 2026.
Reynolds has 34 years of accounting and finance experience advising listed and private companies. He was a partner at PwC for 20 years, specialising in audit, transaction services and capital markets, and retired in December 2025. At PwC he led the London Assurance practice and the private equity portfolio company practice, and served as relationship partner for several UK-listed and international companies, including investment trusts. His advisory work has also covered strategy, M&A, internal audit and tax. Reynolds currently serves as a Non-Executive Director of Biopharma Credit PLC, an investment trust providing debt capital to the life sciences industry, and of the law firm Simmons & Simmons.
The company stated that no further information is required to be disclosed under UKLR 6.4.8 of the Financial Conduct Authority Listing Rules. Investor queries may be directed to Holly Kidd, Company Secretary, at GPMS Corporate Secretary Limited.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.